Recurrent Glioblastoma Multiforme : RTOG 0929

A RANDOMIZED PHASE VII STUDY OF ABT--888 IN COMBINATION WITH TEMOZOLOMIDE IN TEMOZOLOMIDE REISISTANT GLIOBLASTOMA (IRB #235086)


A randomized Phase I/II study of ABT-888 in combination with temozolomide in recurrent (temozolomide resistant) glioblastoma (RTOG 0929) 

  • Histologically proven intracranial glioblastoma or gliosarcoma (Phase II) or any high-grade glioma(Phase I).
  • Imaging confirmation of tumor progression or re-growth. Phase II patients must have had 2 adjuvant cycles of temozolomide and may not have more than 2 prior regimens for recurrent disease
  • Phase I patients may not have more than 3 prior regimens of treatment

ABT-888 is an orally bioavailable PARP inhibitor that possesses an excellent efficacy and pharmacokinetic profile. ABT-888 enhances the anti-tumor activity of DNA damaging agents including temozolomide, irinotecan, cyclophosphamide, and cisplatin.

  • Arm 1: ABT-888 plus temozolomide (days 1-21 of a 28-day cycle) (MTD from phase I)
  • Arm 2: ABT-888 plus temozolomide (days 1-5 of a 28-day cycle)

Surasak Phuphanich, MD, FAAN
Director, Neuro-oncology Program
phuphanich@cshs.org
Phone: (310) 423-8100

Heather Chen
Program Coordinator
heather.chen@cshs.org
Phone: (310) 248-6773

print button
WP2